Conjunctivitis Treatment is the largest segment driving the growth of the global Eye Flu (Conjunctivitis) Market


Eye flu, also known as conjunctivitis, is an eye infection that causes redness, tearing, and itching of the eyes. It spreads through direct contact with an infected person or contaminated items. Effective treatment options help control symptoms and prevent contagiousness.

The global Eye Flu (Conjunctivitis) Market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the major trends in the eye flu treatment market is the introduction of innovations in drug delivery systems. Leading players are focused on developing advanced drug formulations like gels, ointments, and eye drops for better treatment outcomes. For instance, generic ophthalmic gel and ointment formulations have gained popularity due to their longer lasting effect, controlled drug release, and low preservatives content compared to conventional eye drops. This has significantly boosted their adoption among patients.

SWOT Analysis
Strength: Eye flu is usually not a serious condition and resolves on its own within a week with proper self-care. This makes it easier to treat without significant health issues.
Weakness: Eye flu is highly contagious and spreads through direct contact with discharge from eyes or contact with surfaces. This makes it challenging to control spread.
Opportunity: Increasing awareness about hygiene and sanitation can help reduce incidence of eye flu. Proper treatment seeks to shorten duration and relieve symptoms.
Threats: Repeated bouts may increase risk of complications. New antibiotic-resistant strains are a growing threat.

Key Takeaways
The global eye flu (conjunctivitis) market is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing prevalence of allergic conjunctivitis. According to estimates, allergic conjunctivitis affects over 30% of the global population. Advances in treatment options along with growing awareness are supporting market expansion.

Regional analysis: North America accounts for the largest share of the global eye flu market due to major players domiciled in the region and advanced healthcare infrastructure. However, Asia Pacific is emerging as the fastest growing market led by countries like China and India. Rising living standards and growing medical tourism are fueling regional growth.

Key players operating in the eye flu (conjunctivitis) market are Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, Cipla. These companies are focused on developing advanced treatments to widening patient access and strengthen market position.


  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it